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3D heart models for planning of percutaneous tricuspid interventions
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BACKGROUND Transcatheter tricuspid valve therapies are an
emerging ﬁeld in structural cardiac interventions. 3D rapid prototyp-
ing of the heart structures can deliver a helpful tool to plan, test and
carry out percutaneous tricuspid procedures.
METHODS Multislice CT Scan (MSCT) was collected from 8 patients
screened while being assessed for potential percutaneous tricuspid
valve intervention. The imaging data were analyzed and manipulated
using dedicated 3D software to create a computer generated 3D mesh
of the right heart and inferior vena cava anatomy. The 3D models were
processed into solid slices by using 3D printing stereo-lithography,
allowing the creation of ﬂexible silicone heart models. Multiplanar
reconstruction of the MSCT was used to measure the following vari-
ables: heart chambers dimension, tricuspid valve diameters and IVC
dimensions. A simulation of the tricuspid device steering capability
within the heart structures has been computed, then replicated in the
real solid printed model. CT dimensional and steering parameters
were compared with the 3D-printed model for consistency. Usability
of the model was assessed evaluating the feedback (ranging from
unsatisfactory to excellent) by two independent operators.
RESULTS Mimicking the patient speciﬁc right heart structures, the
catheter steering angles and the identiﬁcation of the target point were
simulated under multimodality imaging guidance (Fluoroscopic and
Echocardiography). The ability to position the transcatheter device to
the target area was obtained as well as the maneuverability was
evaluated revealing implant feasibility. The steerability of the trans-
catheter device to the target area was successful in all the simulations,
reﬂecting a minimal error (3%) in the angles calculated from the
computational simulation. Usability of the model was assessed as
excellent by operators in all the cases.
CONCLUSIONS 3D printing is helpful clinical tool for planning and
training operators in the early stage of this innovative interventions,
as percutaneous tricuspid procedures. 3D models allowed the
achievement of tangible feedback without the need of extensive
preclinical animal testing, individualizing the procedural planning
and improving the procedural outcomes.CATEGORIES STRUCTURAL: Valvular Disease: Other
KEYWORDS Modeling, Planning, Tricuspid regurgitation
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BACKGROUND Frailty is known to correlate with mortality in car-
diovascular diseases. Gait speed, a commonly accepted frailty metric,
has not been well validated in patients undergoing transcatheter
aortic valve replacement (TAVR). Recently, psoas muscle area (PMA),
measured by computed tomography, has been shown to be related to
outcomes in cardiovascular surgery. The purpose of this study was to
determine if PMA can predict mortality as a marker for frailty in pa-
tients following TAVR.
METHODS We retrospectively reviewed 232 consecutive patients un-
dergoing TAVR. Cross-sectional areas of the psoas muscles at the level
of the fourth lumbar vertebra were measured for each patient. PMA
was normalized for height (mm2/m2). The primary endpoint was all-
cause mortality at 90 days and 1 year. The association between PMA
and clinical variables were assessed using multivariate linear regres-
sion model. The association between mortality and clinical variables
including PMA/m2 were assessed using multivariate Cox proportional
hazards model. Gait speed was tested preprocedure in 123 patients,
and was included in subanalysis.
RESULTS Higher PMA/m2 was associated with male gender (r ¼ 0.410,
p <0.001), younger patient (r ¼ 0.234, p <0.001), and better ejection
fraction (r ¼ 0.243, p <0.001). The 90 day and 1 year mortality were
15.9% and 27.1% (mean Society of Thoracic Surgeons score 8.58%).
Importantly, after accounting for multiple risk factors including New
York Heart Association class, prior myocardial infarction, prior stroke,
and estimated glomerular ﬁltration rate, PMA signiﬁcantly correlated
with mortality at 90 days and 1 year mortality (Adjust Hazard Ratio ¼
1.517 [95% CI: 1.19 - 1.93] and 1.245 [95% CI: 1.05 - 1.48], respectively).
When PMA was stratiﬁed into tertiles, Kaplan-Meier analysis
demonstrated the lowest survival probability in patients with the
smallest PMA in both 90 days and 1 year (73.5%, and 60.4%, log-rank
p ¼ 0.010, and 0.048, respectively). In subanalysis, receiver operating
curve showed PMA/m2 in combination with gait speed 0.4 m/s had
the greatest discrimination ability for mortality at both 90 days and 1
year, compared with either PMA/m2 or gait speed alone.
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day and 1 year mortality following TAVR, and further augments gait
speed as a frailty test in patients undergoing TAVR without additional
cost.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) has
been designed to treat elderly patients with severe aortic stenosis at
high risk for surgery. The safety and effectiveness of TAVI have been
demonstrated in numerous studies. The self expanding CoreValve
prosthesis is implanted retrogradely with vascular access usually via
the femoral or subclavian arteries. However, in certain patients these
access routes are either not possible or are deemed to carry a high risk
of vascular injury. We report the results of the EURyDICE Registry:
EURopean DIrect Aortic Corevalve Experience, a multi-centre expe-
rience with the self expanding CoreValve prosthesis implanted
through a direct aortic approach (DA) in patients considered high risk
surgical candidates.
METHODS This multi-centre experience comprises patients treated in
the 20 centres in 9 countries in Europe and in Israel, between June
2008 and January 2015. A standard dataset was circulated between
center, all deﬁnitions were collected according to VARC II.
RESULTS A total of 664 cases have been collected. Mean age of the
population was 81.06.5 years, 49% were female, mean logistic
EuroSCORE was 25.516.1; 532 patients were in NYHA class  III
(80%). Peripheral vasculopathy was the principal exclusion criteria
from trans-femoral TAVI and was present in 424 patients (64%); 394
patients had coronary artery disease (59%) and 140 patients had un-
dergone previous coronary artery bypass surgery. TAVI procedure was
performed in 280 of cases (42%) through a righ anterior mini-thora-
cotomy in the 2nd intercostal space or via an upper hemi-sternotomy
in the others 384 patients. A size 29mm CoreValve was implanted in
287 patients (43%). Procedural success was achieved in 647 patients,
98% of cases. Five patients required a 2nd valve implanted and 4
patients had >moderate para-valvular regurgitation; 30-da mortality
was 8%. Fourteen patients experience stroke (2.1%) and 97 patients
(14%) required a new permanent pacemaker; 93% of patients had
aortic regurgitation <2þ/4þ. Median post-operative hospitalization
was 9 days.
CONCLUSIONS Direct aortic access is a feasible approach for TAVI
with the self expanding CoreValve prosthesis. These initial results ofthe EURyDICE Registry are encouraging given the high risk patient
cohort and evidence the fact that proximal approached should results
in higher valve deployment control and accurate implantation,
translating into lower incidence of pace-maker implantation and para-
valvular regurgitation.
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BACKGROUND Among high-risk patients with severe aortic stenosis
(AS), transcatheter aortic valve replacement (TAVR) with a self-
expanding prosthesis has been shown to improve 2-year survival
when compared with surgical aortic valve replacement (SAVR). For
many elderly patients, however, quality of life (QoL) may be at least as
important as length of life. To date, no large-scale studies have
examined the durability of QoL improvement with TAVR vs. SAVR
beyond 1-year follow-up.
METHODS We evaluated health status among 797 high-risk patients
with severe AS who were randomized to either TAVR or SAVR in the
CoreValve US Pivotal High Risk Trial. Health status was assessed at
baseline, 1 month, 6 months, 1 year, and 2 years using the Kansas City
Cardiomyopathy Questionnaire (KCCQ), Short Form-12 (SF-12), and
the EuroQoL-5D (EQ-5D). Longitudinal random-effects growth curve
models were used to examine the relative impact of TAVR versus
SAVR over time while adjusting for baseline health status and key
clinical variables.
RESULTS When compared to baseline, among surviving patients
there was substantial improvement in the KCCQ Overall Summary
score at 2-year follow-up with both TAVR (22.2; 95% CI 18.6-25.8; p <
0.0001) and SAVR (18.7; 95% CI 14.8-22.7; p < 0.0001) (see Table).
Although patients treated with TAVR demonstrated more rapid QoL
improvement than with SAVR, there were no signiﬁcant differences
between the two groups at 1 and 2 years. Similar results were seen
for the individual KCCQ subscales as well as the SF-12 physical
function domain (see Table). Moreover, the extent of QoL
improvement at 1 and 2 years was similar for patients treated via
either the iliofemoral (IF) and non-IF approach.
CONCLUSIONS Among high-risk patients with severe AS enrolled in
the CoreValve US Pivotal High Risk Trial, initial QoL improvements
with both TAVR and SAVR were largely sustained through 2-year
follow-up. When coupled with the improved survival and more rapid
QOL improvement seen with TAVR, these ﬁndings suggest that TAVR
should be considered as a reasonable alternative to SAVR for high-risk
patients with severe AS.
